CD8A and neoplasm: In addition, bufalin and PD‐L1 antibody combination treatment activated a potent antitumor immune response with the increase in the number (Figure 6H; Figure S5B, Supporting Information) and activity (Figure 6I; Figure S5C, Supporting Information) of tumor‐infiltrating CD8+ T cells, and eventually elicits prominent tumor growth inhibition.